Date & Time of Session - 9/5/25 - from 12:00 - 1:00PM

Overview: What was once thought to be a rare disease, the prevalence of transthyretin cardiac amyloidosis (ATTR-CM) is increasing due to improved diagnostic tools increasing awareness. Treatment options for ATTR-CM continue to expand with two new FDA-approved therapies over the last two years. Multiple other therapies are in clinical trials pending results and publication. With many new medications, cost can be a significant barrier to access these therapies. Pharmacists can serve a vital role in counseling, monitoring therapy, and reducing medication access barriers.

Objectives
Upon completion of this activity, participants will be able to:
1. Review the definition, pathophysiology, and epidemiology of cardiac amyloidosis
2. Discuss the diagnosis of cardiac amyloidosis and differentiate between the two principal subtypes
3. Discuss treatment options to avoid in transthyretin amyloidosis cardiomyopathy
4. Analyze current and evolving literature surrounding the treatment of transthyretin amyloidosis cardiomyopathy

    Target Audience
    Pharmacists, residents, and students

    Special Services
    If you require special assistance to attend this event, please call Megan Russel at (304) 550-0896.

    Speaker

    Adam Roskam, PharmD
    PGY2 Cardiology Pharmacy Resident
    UK College of Pharmacy - Lexington, Kentucky

    Session date: 
    09/05/2025 - 12:30pm EDT to 11/03/2025 - 11:59pm EST
    Add to calendar: 
    • 1.00 ACPE

      In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

      This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

    • 1.00 Participation
      UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
    Please login or register to take this course.
    Faculty List: 
    Speaker(s)

    Adam Roskam, PharmD

    has no relevant financial relationships to disclose at this time.